iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024
NASHUA, N.H. and PARIS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader...
News
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
DSMC has reviewed the safety and pharmacokinetic data from Cohort 2 and recommended that the study proceed to enroll patients...
Harvard Bioscience to Showcase Innovative Technologies at Society for Neuroscience (SfN) Annual Meeting 2024
New products complement an already extensive range of products enabling fundamental advancements in neuroscience researchHOLLISTON, Mass., Oct. 03, 2024 (GLOBE...
Spur Therapeutics Announces Oral Presentation Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
LONDON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spur Therapeutics, formerly Freeline Therapeutics, today announced that it will present updated clinical...
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting...
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
Media Release SYDNEY, AUSTRALIA, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”),...
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
BASKING RIDGE, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Nusano Adds to Executive Leadership Team in Advance of 2025 Commercialization
VALENCIA, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Nusano, Inc., a physics company transforming the production of medical radioisotopes, today...
Ascend Clinical Wins Silicon Valley Business Journal Structures Award
SUNNYVALE, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Eurofins Ascend Clinical announces that it has won a 2024 Structures award...
ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth
LOS ANGELES, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and...
Bionano Adjourns Special Meeting of Stockholders to October 30, 2024
Special Meeting of Stockholders Adjourned Due to Lack of QuorumSAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc....
Spectral Medical Provides September Tigris Trial Update
• 132 patients enrolled TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),...
Closes Units for Debt Settlement
TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF)...
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell...
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts Ongoing...
Neural Therapeutics Inc. Announces Letter of Intent with Leading German Hemp-Based Product Retailer “Hanf.com”
Toronto, Ontario--(Newsfile Corp. - October 3, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company...
DATAcc by DiMe Awarded FDA Grant to Boost Use of Sensor-Based Digital Health Technologies in Clinical Trials
DATAcc is creating an open-source industry guide to address market challenges by bringing clarity on how and why to include...
XRP Healthcare and Foventa Collaborate for Africa’s Premier Lab Expo
DUBAI, UAE, Oct. 3, 2024 /PRNewswire/ -- XRP Healthcare is proud to announce its strategic partnership with Foventa for the...
Positive Data from the First Part of IRLAB’s Phase I Study with the Drug Candidate IRL757
GOTHENBURG, SE / ACCESSWIRE / October 3, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, October 3 2024 - IRLAB Therapeutics...
